Grant,
I've been searching for a donor for almost a year now, so I'll be watching your progress closely.
Good luck!!!
Tracy
Forums
-
Tracy J - Name: Tracy Jalbuena
- Who do you know with myeloma?: Me
- When were you/they diagnosed?: 2014
- Age at diagnosis: 42
Re: Allo General Questions
Hi Tracy,
I'm not sure where you have searched for a donor but I actually had 3 very good matches from Germany. Good luck, I hope you find someone soon!
Ta
Grant
I'm not sure where you have searched for a donor but I actually had 3 very good matches from Germany. Good luck, I hope you find someone soon!
Ta
Grant
-
Grant - Name: Grant
- Who do you know with myeloma?: myself
- When were you/they diagnosed?: April 2014
- Age at diagnosis: 43
Re: Allo General Questions
Hi Cmolinaro!
How are you? Eventually you did not have an allo or auto SCT, you only take Revimid and dex, is that true?
How are you? Eventually you did not have an allo or auto SCT, you only take Revimid and dex, is that true?
-
chen5631867 - Name: George Chen
- Who do you know with myeloma?: My Spouse
- When were you/they diagnosed?: Feb. 25, 2011
- Age at diagnosis: 53
Re: Allo General Questions
Hi Grant,
"I am about to go in for an allo transplant (unrelated donor) and was wondering what Mark meant by "I did a partially T cell depleted allo with myeloablative conditioning"? Never heard of a T cell depleted allo or myeloablative conditioning ..."
I hope all is going well for you. Most likely you have already used myeloablative conditioning - if you did an auto, you used myeloablative conditioning. There some questions about conditioning and what terms like reduced intensity, etc mean. Here is a link that explains.
"The intensity of conditioning regimens can vary substantially, and when selecting the optimal conditioning regimen for any given patient, disease-related factors such as diagnosis and remission status, as well as patient-related factors including age, donor availability, and presence of comorbid conditions, need to be considered. In rare situations, such as children with severe combined immunodeficiency1 or patients with severe aplastic anemia who have syngeneic donors, HCT can be performed without the administration of a preparative regimen.
Although full consensus has not been reached within the HCT community, conditioning regimens have been classified as high-dose (myeloablative), reduced-intensity, and nonmyeloablative, following the Reduced-Intensity Conditioning Regimen Workshop, convened by the Center for International Blood and Marrow Transplant Research (CIBMTR) during the Bone Marrow Transplantation Tandem Meeting in 2006.2 During this meeting, 56 HCT professionals representing 44 institutions from 9 countries agreed on criteria (previously known as the Champlin criteria) to define the general characteristics of a reduced-intensity conditioning (RIC) regimen (Table 1). Based on these criteria, myeloablative, or “high-dose” regimens, consisting of alkylating agents (single or multiple) with or without TBI, are expected to ablate marrow hematopoiesis, not allowing autologous hematologic recovery. In contrast, nonmyeloablative regimens, although causing minimal cytopenias, do not require stem cell support.3 Regimens that do not fit the definition for myeloablative or nonmyeloablative conditioning are classified as RIC regimens: they result in potentially prolonged cytopenias, and they require hematopoietic stem cell support. What differentiates RIC regimens from myeloablative regimens is that the dose of alkylating agents or TBI is generally reduced by ≥30%. It is important to recognize that the intensity of regimens classified as reduced-intensity by these criteria can vary substantially and represents a continuum. Examples of reduced-intensity and nonmyeloablative regimens are shown in Table 2."
http://www.bloodjournal.org/content/124/3/344.figures-only?sso-checked=true
T cell depletion is a method of preventing/reducing the chances GVHD, particularly extensive chronic GVHD.. I used an in vivo depletion via ATG-F. There are multiple methods. Here is a link about ATG if interested. I have put this up many time previously.
"Polyclonal ATG as well as the monoclonal alemtuzumab (anti-CD52) enhance engraftment and reduce the incidence of severe GvHD after standard as well as reduced intensity conditioning allogeneic stem cell transplantation from matched and mismatched unrelated donors.13,14,25,26 The potential of these serotherapies to enhance engraftment and prevent severe GvHD is at least in part due to the in vivo T-cell depletion associated with their use."
http://www.haematologica.org/content/93/9/1343
Mark
"I am about to go in for an allo transplant (unrelated donor) and was wondering what Mark meant by "I did a partially T cell depleted allo with myeloablative conditioning"? Never heard of a T cell depleted allo or myeloablative conditioning ..."
I hope all is going well for you. Most likely you have already used myeloablative conditioning - if you did an auto, you used myeloablative conditioning. There some questions about conditioning and what terms like reduced intensity, etc mean. Here is a link that explains.
"The intensity of conditioning regimens can vary substantially, and when selecting the optimal conditioning regimen for any given patient, disease-related factors such as diagnosis and remission status, as well as patient-related factors including age, donor availability, and presence of comorbid conditions, need to be considered. In rare situations, such as children with severe combined immunodeficiency1 or patients with severe aplastic anemia who have syngeneic donors, HCT can be performed without the administration of a preparative regimen.
Although full consensus has not been reached within the HCT community, conditioning regimens have been classified as high-dose (myeloablative), reduced-intensity, and nonmyeloablative, following the Reduced-Intensity Conditioning Regimen Workshop, convened by the Center for International Blood and Marrow Transplant Research (CIBMTR) during the Bone Marrow Transplantation Tandem Meeting in 2006.2 During this meeting, 56 HCT professionals representing 44 institutions from 9 countries agreed on criteria (previously known as the Champlin criteria) to define the general characteristics of a reduced-intensity conditioning (RIC) regimen (Table 1). Based on these criteria, myeloablative, or “high-dose” regimens, consisting of alkylating agents (single or multiple) with or without TBI, are expected to ablate marrow hematopoiesis, not allowing autologous hematologic recovery. In contrast, nonmyeloablative regimens, although causing minimal cytopenias, do not require stem cell support.3 Regimens that do not fit the definition for myeloablative or nonmyeloablative conditioning are classified as RIC regimens: they result in potentially prolonged cytopenias, and they require hematopoietic stem cell support. What differentiates RIC regimens from myeloablative regimens is that the dose of alkylating agents or TBI is generally reduced by ≥30%. It is important to recognize that the intensity of regimens classified as reduced-intensity by these criteria can vary substantially and represents a continuum. Examples of reduced-intensity and nonmyeloablative regimens are shown in Table 2."
http://www.bloodjournal.org/content/124/3/344.figures-only?sso-checked=true
T cell depletion is a method of preventing/reducing the chances GVHD, particularly extensive chronic GVHD.. I used an in vivo depletion via ATG-F. There are multiple methods. Here is a link about ATG if interested. I have put this up many time previously.
"Polyclonal ATG as well as the monoclonal alemtuzumab (anti-CD52) enhance engraftment and reduce the incidence of severe GvHD after standard as well as reduced intensity conditioning allogeneic stem cell transplantation from matched and mismatched unrelated donors.13,14,25,26 The potential of these serotherapies to enhance engraftment and prevent severe GvHD is at least in part due to the in vivo T-cell depletion associated with their use."
http://www.haematologica.org/content/93/9/1343
Mark
-
Mark11
Return to Treatments & Side Effects